ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
12 announcements
Caplin Point Laboratories concluded its 35th Annual General Meeting on September 25, 2026. Key business included adopting financial statements and approving the final dividend declaration.
Caplin Point Laboratories clarified that the recent increase in its stock's trading volume is market-driven. The company confirmed no undisclosed material information exists regarding this movement.
Caplin Point Laboratories Limited shared a weblink for its 35th AGM Notice and Annual Report for FY 2025-26. The communication targets shareholders with unregistered email addresses.
Caplin Point Laboratories Limited scheduled its 35th Annual General Meeting for September 25, 2026. Key agenda items include adopting financial statements and declaring a ₹4 final dividend.
Caplin Point Laboratories Limited submitted its Annual Report for FY 2025-26. The company's 35th Annual General Meeting is scheduled for September 25, 2026.
Caplin Point Laboratories has clarified that recent trading volume spikes are market-driven. The company confirms it has no undisclosed price-sensitive information.
Caplin reported strong Q1FY27 growth with 20% revenue and 19% PAT increase. Management is scaling capacity towards 15+ sterile lines while maintaining a debt-free balance sheet and high cash reserves.
Caplin Point delivers strong Q1FY27 growth driven by a 3x surge in US revenue. Management is aggressive on vertical integration and digitalization but faces near-term capacity constraints at key plants.
Caplin Point Laboratories Ltd reported revenue from operations of ₹610.4 Cr (+19.6% YoY) and net profit of ₹179.1 Cr (+18.8% YoY) for Q1 FY27.
Caplin Point reported strong Q4 FY26 results with revenue doubling to INR 2,300cr and liquid assets tripling. Strategy focuses on massive injectable expansion and LATAM private market depth.
Caplin Point delivers a strong FY26 with revenue doubling over five years and a massive push into US injectables.
Caplin Point Laboratories Ltd reported revenue from operations of ₹600.2 Cr (+19.5% YoY) and net profit of ₹172.9 Cr (+19.0% YoY) for Q4 FY26.